Evidence map›Paper›PMID 30712055›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

Comparison of Physical Crossmatch and Virtual Crossmatch to Identify Preexisting Donor-Specific Human Leukocyte Antigen (HLA) Antibodies and Outcome Following Kidney Transplantation.

Bo Peng, Quan Zhuang, Meng Yu, Junhui Li, Yun Liu, Lijun Zhu, Yingzi Ming

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Bo PengThe Transplantation Center of The Third Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Quan ZhuangThe Transplantation Center of The Third Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Meng YuThe Transplantation Center of The Third Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Junhui LiThe Transplantation Center of The Third Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Yun LiuThe Transplantation Center of The Third Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Lijun ZhuThe Transplantation Center of The Third Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Yingzi MingThe Transplantation Center of The Third Xiangya Hospital, Central South University, Changsha, Hunan, China (mainland).
Third Xiangya Hospital · CNCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Physical crossmatch (PXM) and virtual crossmatch (VXM) are applied to identify preexisting donor-specific human leukocyte antigen (HLA) antibodies in patients awaiting kidney transplantation. Recently, high-resolution epitope analysis has emerged as a novel strategy for VXM. A retrospective clinical study compared PXM with VXM before kidney transplantation and recipient outcome following transplantation. MATERIAL AND METHODS Between August 2017 and March 2018, 239 patients underwent crossmatching and 94 patients received a donor kidney. A complement-dependent cytotoxicity (CDC) PXM assay and VXM using serological and epitope analysis identified donor-specific antibodies (DSA). Crossmatch results and clinical outcome at 3 months were compared. RESULTS VXM identified serological DSA (sDSA), verified epitope DSA, and total epitope DSA in 74 (31.0%), 39 (16.3%), and 49 (20.5%) cases, respectively. Eleven cases (4.6%) had a positive PXM detected by the CDC assay. Of 94 kidney transplant recipients, 21 had preexisting sDSA but were negative in PXM; there was 1 case of delayed graft function (DGF) and no cases of hyperacute rejection or acute rejection. Of the rest of the 73 recipients who were negative for sDSA, 8 had acute rejection (P=0.253) and 19 had DGF (P=0.037). No significant differences were found in graft survival at 3 months. CONCLUSIONS High-resolution epitope analysis identified fewer cases with DSA compared with serological analysis. Because patients with and without sDSA had a similar short-term outcome in the setting of a negative PXM, the presence of preexisting sDSA, determined by VXM, should not be an absolute contraindication for kidney transplantation.

Indexed as

AdultAntibodiesBlood Grouping and CrossmatchingFemaleGraft RejectionGraft SurvivalHistocompatibility Antigens Class IHLA AntigensHumansKidney TransplantationMaleMiddle AgedRetrospective StudiesTissue DonorsAntibodiesHistocompatibility Antigens Class IHLA Antigens

Identifiers

PMID30712055
PMCPMC6369651
OpenAlexW2911705945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.